Idenix Leads Baupost To Best Month In Five Years; Klarman Explains Bio-tech Investments

In the second quarter letter, Klarman spoke of the profits it made on investments such as Idenix Pharmaceuticals Inc (NASDAQ:IDIX). The biotech company helped make June Baupost’s best month in five years. Idenix was acquiredby Merck & Co., Inc. (NYSE:MRK)’s wholly-owned subsidiary Imperial Blue Corporation. Baupost exited the investment in early August. Baupost’s returns in the second quarter were driven chiefly by its public equity portfolio, backed up by positive performance in distressed debt, real estate, and structured products as well.

See Baupost 2013 letter to investors, which discusses Greek investments, distressed debt, real estate and more, here

Note...